These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34681879)

  • 21. TEX19 promotes ovarian carcinoma progression and is a potential target for epitope vaccine immunotherapy.
    Xu Z; Tang H; Zhang T; Sun M; Han Q; Xu J; Wei M; Yu Z
    Life Sci; 2020 Jan; 241():117171. PubMed ID: 31843525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glycoproteomic identification of potential glycoprotein biomarkers in ovarian cancer proximal fluids.
    Kuzmanov U; Musrap N; Kosanam H; Smith CR; Batruch I; Dimitromanolakis A; Diamandis EP
    Clin Chem Lab Med; 2013 Jul; 51(7):1467-76. PubMed ID: 23241603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma.
    McIntosh MW; Liu Y; Drescher C; Urban N; Diamandis EP
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4422-8. PubMed ID: 17671125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
    Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
    Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels.
    Lancaster JM; Sayer RA; Blanchette C; Calingaert B; Konidari I; Gray J; Schildkraut J; Schomberg DW; Marks JR; Berchuck A
    Int J Gynecol Cancer; 2006; 16(4):1529-35. PubMed ID: 16884361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Value of Serum CA125 in the Diagnosis of Borderline Tumors of the Ovary: A Subanalysis of the Prospective Multicenter ROBOT Study.
    Fotopoulou C; Sehouli J; Ewald-Riegler N; de Gregorio N; Reuss A; Richter R; Mahner S; Kommoss F; Schmalfeldt B; Fehm T; Hanker L; Wimberger P; Canzler U; Pfisterer J; Kommoss S; Hauptmann S; du Bois A;
    Int J Gynecol Cancer; 2015 Sep; 25(7):1248-52. PubMed ID: 25978292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.
    Taylor DD; Gercel-Taylor C; Parker LP
    Gynecol Oncol; 2009 Oct; 115(1):112-120. PubMed ID: 19647308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A serum based analysis of ovarian epithelial tumorigenesis.
    Nolen B; Marrangoni A; Velikokhatnaya L; Prosser D; Winans M; Gorelik E; Lokshin A
    Gynecol Oncol; 2009 Jan; 112(1):47-54. PubMed ID: 19007974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical usefulness of high levels of C-reactive protein for diagnosing epithelial ovarian cancer.
    Yang D; Li H; Sun X; Yang S; Wang K; Liu Z
    Sci Rep; 2020 Nov; 10(1):20056. PubMed ID: 33208875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical applicability of multi-tumor marker protein chips for diagnosing ovarian cancer.
    Bian J; Li B; Kou XJ; Wang XN; Sun XX; Ming L
    Asian Pac J Cancer Prev; 2014; 15(19):8409-11. PubMed ID: 25339038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oviductal glycoprotein (OVGP1, MUC9): a differentiation-based mucin present in serum of women with ovarian cancer.
    Maines-Bandiera S; Woo MM; Borugian M; Molday LL; Hii T; Gilks B; Leung PC; Molday RS; Auersperg N
    Int J Gynecol Cancer; 2010 Jan; 20(1):16-22. PubMed ID: 20130498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer.
    Nielsen JS; Jakobsen E; Hølund B; Bertelsen K; Jakobsen A
    Int J Gynecol Cancer; 2004; 14(6):1086-96. PubMed ID: 15571614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer.
    Yu-Rice Y; Edassery SL; Urban N; Hellstrom I; Hellstrom KE; Deng Y; Li Y; Luborsky JL
    Reproduction; 2017 Mar; 153(3):277-284. PubMed ID: 27965399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.
    Hurley LC; Levin NK; Chatterjee M; Coles J; Muszkat S; Howarth Z; Dyson G; Tainsky MA
    Cancer Biomark; 2020; 27(3):407-421. PubMed ID: 32083570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum antiglycan antibody detection of nonmucinous ovarian cancers by using a printed glycan array.
    Jacob F; Goldstein DR; Bovin NV; Pochechueva T; Spengler M; Caduff R; Fink D; Vuskovic MI; Huflejt ME; Heinzelmann-Schwarz V
    Int J Cancer; 2012 Jan; 130(1):138-46. PubMed ID: 21351089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.
    Dijkgraaf EM; Santegoets SJ; Reyners AK; Goedemans R; Wouters MC; Kenter GG; van Erkel AR; van Poelgeest MI; Nijman HW; van der Hoeven JJ; Welters MJ; van der Burg SH; Kroep JR
    Ann Oncol; 2015 Oct; 26(10):2141-9. PubMed ID: 26216383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
    Shen Y; Li L
    Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoclonal antibody, Mab 12C3, is a sensitive immunohistochemical marker of early malignant change in epithelial ovarian tumors.
    Yamada K; Ohkawa K; Joh K
    Am J Clin Pathol; 1995 Mar; 103(3):288-94. PubMed ID: 7872250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
    Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
    Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Agreement for tumor grade of ovarian carcinoma: analysis of archival tissues from the surveillance, epidemiology, and end results residual tissue repository.
    Matsuno RK; Sherman ME; Visvanathan K; Goodman MT; Hernandez BY; Lynch CF; Ioffe OB; Horio D; Platz C; Altekruse SF; Pfeiffer RM; Anderson WF
    Cancer Causes Control; 2013 Apr; 24(4):749-57. PubMed ID: 23378140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.